Why invest

Our successful business model provides a solid platform for growth. We combine a diverse portfolio with excellent financial discipline to deliver outstanding value for shareholders.

A firm foundation for future growth

  • Leading supplier of both generic injectable and non-injectable products in the US
  • Leading market position in MENA (second largest pharmaceutical company by sales) and a growing presence in Europe
  • Trusted partner known for our commitment to quality and reliability of supply
  • Broad portfolio of high-quality products¬†
  • Agile supply chain, flexible manufacturing and leading technical capabilities
$ 2,875 m Group core revenue
$ 707 m Group core operating profit
18 % Return on capital invested

An increasingly diverse portfolio and pipeline

  • Growing presence in specialty and complex products, which offer less competition and more potential for future margin growth
  • Focus on higher-value therapeutic areas such as cardiovascular, central nervous system (CNS) and oncology
  • Annual investment in R&D to ensure we are consistently
    launching new products across our markets
  • Strong track record of value-creating partnerships, strategic
    acquisitions and geographic expansion, to enhance pipeline
    and access to new markets
5 % R&D spend as % of revenue
157 launches in 2023 across our markets
250 + projects in pipeline

A strong balance sheet and robust cash generation

  • Good cash flow generation, with $608 million operating cash flow in 2023
  • Highly disciplined approach to cash management and acquisitions
  • Strong balance sheet that provides financial flexibility to
    support future growth, and low leverage of 1.2x net debt/
    core EBITDA
1.2 x net debt/core EBITDA
$ 608 m operating cash flow
21 % operating cash flow/revenue

A proven track record of delivery for shareholders

  • A clear vision for growth
  • Group revenue compound annual growth rate (CAGR) of 7% and core EBITDA CAGR of 8% since 2018
  • Total shareholder return of 76% over the last ten years
  • Progressively increasing dividend
17.7 % return on invested capital
5 % group revenue growth at five-year CAGR
76 % TSR over last ten years

All figures for year ending 31 December 2023. 

Hikma’s Executive Vice Chairman and President of MENA Joins Rakuten Medical’s Board of Directors

Press Release, Corporate 07 March 2024

Hikma delivers strong 2023 performance and a positive outlook for 2024

Press Release, Financial Results 22 February 2024

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

Press Release, Corporate 21 February 2024

Hikma launches Fentanyl Citrate Injection, USP, in a prefilled syringe in the US

Press Release, Product 20 February 2024

Hikma launches Alvimopan Capsules in the US

Press Release, Product 13 February 2024

Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...

Press Release, Business Development 12 February 2024

Notice of preliminary results

Press Release, Financial Results 05 February 2024

Hikma announces US launch of COMBOGESIC® IV

Press Release, Product 05 February 2024

Hikma appoints Julie Hill, as Senior Vice President, Corporate Quality Compliance/Health and Safety

Press Release, Leadership 01 February 2024

Hikma Announces Agreement in Principle for Nationwide US Opioid Settlement Framework

Press Release, Corporate 01 February 2024
Related content

Recent results